Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction

Gilman D. Plitt, Jordan T. Spring, Michael J Moulton, Devendra K. Agrawal

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Heart failure with preserved ejection fraction (HFpEF) continues to be a major challenge for clinicians. Many crucial aspects of the syndrome remain unclear, including the exact pathophysiology, early diagnosis, and treatment. Patients with HFpEF are often asymptomatic late into the disease process, and treatment with medications commonly used in heart failure with reduced ejection fraction (HFrEF) has not been proven to be beneficial. In addition, the confusion of similar terms with HFpEF, such as diastolic heart failure, and diastolic dysfunction (DD), has led to a misunderstanding of the true scope of HFpEF. Areas covered: In this review, authors highlight the differences in terminology and critically review the current knowledge on the underlying mechanisms, diagnosis, and latest treatment strategies of HFpEF. Expert commentary: While significant advances have been made in the understanding of HFpEF, the definitive diagnosis of HFpEF continues to be difficult. The development of improved and standardized methods for detecting DD has shown promise in identifying early HFpEF. However, even with early detection, there are few treatment options shown to provide mortality benefit warranting further investigation.

Original languageEnglish (US)
Pages (from-to)579-589
Number of pages11
JournalExpert review of cardiovascular therapy
Volume16
Issue number8
DOIs
StatePublished - Aug 3 2018

Fingerprint

Treatment Failure
Heart Failure
Diastolic Heart Failure
Delayed Diagnosis
Therapeutics
Terminology
Early Diagnosis
Mortality

Keywords

  • Biomarkers
  • Diastolic dysfunction
  • HFpEF
  • HFrEF
  • Inflammation

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction. / Plitt, Gilman D.; Spring, Jordan T.; Moulton, Michael J; Agrawal, Devendra K.

In: Expert review of cardiovascular therapy, Vol. 16, No. 8, 03.08.2018, p. 579-589.

Research output: Contribution to journalReview article

@article{5e03b9ca67624fbda0e3df1e6fc05f5b,
title = "Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction",
abstract = "Introduction: Heart failure with preserved ejection fraction (HFpEF) continues to be a major challenge for clinicians. Many crucial aspects of the syndrome remain unclear, including the exact pathophysiology, early diagnosis, and treatment. Patients with HFpEF are often asymptomatic late into the disease process, and treatment with medications commonly used in heart failure with reduced ejection fraction (HFrEF) has not been proven to be beneficial. In addition, the confusion of similar terms with HFpEF, such as diastolic heart failure, and diastolic dysfunction (DD), has led to a misunderstanding of the true scope of HFpEF. Areas covered: In this review, authors highlight the differences in terminology and critically review the current knowledge on the underlying mechanisms, diagnosis, and latest treatment strategies of HFpEF. Expert commentary: While significant advances have been made in the understanding of HFpEF, the definitive diagnosis of HFpEF continues to be difficult. The development of improved and standardized methods for detecting DD has shown promise in identifying early HFpEF. However, even with early detection, there are few treatment options shown to provide mortality benefit warranting further investigation.",
keywords = "Biomarkers, Diastolic dysfunction, HFpEF, HFrEF, Inflammation",
author = "Plitt, {Gilman D.} and Spring, {Jordan T.} and Moulton, {Michael J} and Agrawal, {Devendra K.}",
year = "2018",
month = "8",
day = "3",
doi = "10.1080/14779072.2018.1497485",
language = "English (US)",
volume = "16",
pages = "579--589",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction

AU - Plitt, Gilman D.

AU - Spring, Jordan T.

AU - Moulton, Michael J

AU - Agrawal, Devendra K.

PY - 2018/8/3

Y1 - 2018/8/3

N2 - Introduction: Heart failure with preserved ejection fraction (HFpEF) continues to be a major challenge for clinicians. Many crucial aspects of the syndrome remain unclear, including the exact pathophysiology, early diagnosis, and treatment. Patients with HFpEF are often asymptomatic late into the disease process, and treatment with medications commonly used in heart failure with reduced ejection fraction (HFrEF) has not been proven to be beneficial. In addition, the confusion of similar terms with HFpEF, such as diastolic heart failure, and diastolic dysfunction (DD), has led to a misunderstanding of the true scope of HFpEF. Areas covered: In this review, authors highlight the differences in terminology and critically review the current knowledge on the underlying mechanisms, diagnosis, and latest treatment strategies of HFpEF. Expert commentary: While significant advances have been made in the understanding of HFpEF, the definitive diagnosis of HFpEF continues to be difficult. The development of improved and standardized methods for detecting DD has shown promise in identifying early HFpEF. However, even with early detection, there are few treatment options shown to provide mortality benefit warranting further investigation.

AB - Introduction: Heart failure with preserved ejection fraction (HFpEF) continues to be a major challenge for clinicians. Many crucial aspects of the syndrome remain unclear, including the exact pathophysiology, early diagnosis, and treatment. Patients with HFpEF are often asymptomatic late into the disease process, and treatment with medications commonly used in heart failure with reduced ejection fraction (HFrEF) has not been proven to be beneficial. In addition, the confusion of similar terms with HFpEF, such as diastolic heart failure, and diastolic dysfunction (DD), has led to a misunderstanding of the true scope of HFpEF. Areas covered: In this review, authors highlight the differences in terminology and critically review the current knowledge on the underlying mechanisms, diagnosis, and latest treatment strategies of HFpEF. Expert commentary: While significant advances have been made in the understanding of HFpEF, the definitive diagnosis of HFpEF continues to be difficult. The development of improved and standardized methods for detecting DD has shown promise in identifying early HFpEF. However, even with early detection, there are few treatment options shown to provide mortality benefit warranting further investigation.

KW - Biomarkers

KW - Diastolic dysfunction

KW - HFpEF

KW - HFrEF

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=85050396036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050396036&partnerID=8YFLogxK

U2 - 10.1080/14779072.2018.1497485

DO - 10.1080/14779072.2018.1497485

M3 - Review article

VL - 16

SP - 579

EP - 589

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 8

ER -